Head and Neck Cancer Clinical Trials
Here are the 6 most popular medical studies for head and neck cancer
Small Molecule Inhibitor
NT219 + Cetuximab for Head and Neck Cancer
This trial is testing a new drug, NT219, to see if it is safe and effective against solid tumors. The trial will have two parts, first testing different doses of NT219 to see what is safe, then testing NT219 with another drug, ERBITUX, to see if it is more effective than ERBITUX alone.
Monoclonal Antibodies
REGN6569 + Cemiplimab for Advanced Solid Cancer
This trial is evaluating the safety and efficacy of REGN6956 as monotherapy and in combination with cemiplimab. The primary objective is to assess the safety and tolerability of the combination. Secondary objectives include assessing the preliminary efficacy of the combination as measured by objective response rate, disease control rate, duration of response, progression-free survival, and overall survival.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Head and Neck Cancer
This trial is designed to see if adding lenvatinib to pembrolizumab or using lenvatinib alone is better than standard chemotherapy at treating head and neck squamous cell carcinoma that has progressed after platinum therapy and a PD-1 or anti-PD-L1 inhibitor.
Popular filter options for head and neck cancer trials
Squamous Cell Carcinoma Clinical Trials
View 66 Squamous Cell Carcinoma medical studies.
Small Molecule
TPST-1495 + Pembrolizumab for Cancer
This trial is testing a new drug, TPST-1495, to see if it is safe and effective in treating subjects with advanced solid tumors. The study will also look at the side effects of the drug and how it works in the body.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
SCC Clinical Trials
View 63 SCC medical studies.
Small Molecule
TPST-1495 + Pembrolizumab for Cancer
This trial is testing a new drug, TPST-1495, to see if it is safe and effective in treating subjects with advanced solid tumors. The study will also look at the side effects of the drug and how it works in the body.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
Metastatic Head And Neck Cancer Clinical Trials
View 88 metastatic head and neck cancer medical studies.
Small Molecule
TPST-1495 + Pembrolizumab for Cancer
This trial is testing a new drug, TPST-1495, to see if it is safe and effective in treating subjects with advanced solid tumors. The study will also look at the side effects of the drug and how it works in the body.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
P16 Positive Clinical Trials
View 14 p16 positive medical studies.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
Cytokine Agonist
SAR444245 + Anticancer Therapies for Head and Neck Cancer
This trial is investigating whether the drug SAR444245, when combined with other cancer treatments, will result in a significant increase in the number of people with head and neck squamous cell carcinoma (HNSCC) who respond to the treatment. The trial is divided into three parts, each testing the drug in combination with a different treatment. Part 1 is testing SAR444245 combined with the anti-PD1 antibody pembrolizumab in people who are treatment-naive for recurrent and/or metastatic HNSCC. Part 2 is testing SAR444245 combined with the anti-PD1 antibody pembrolizumab in
Monoclonal Antibodies
Imatinib + Cetuximab for Head and Neck Cancer
This trial tests whether a protein in cancer cells can predict how head and neck tumors respond to a combination of two treatments. Participants will be monitored for 13-16 months to assess the effectiveness.
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Apoptosis Inhibitor
Xevinapant + Chemoradiation for Head and Neck Cancer
This trial will test a new drug (xevinapant) combined with chemotherapy and radiation to fight head and neck cancer. Participants will get up to 4 doses to determine the safest dose, then a larger group will try that dose.
Head And Neck Cancer Clinical Trials With No Placebo
View 88 head and neck cancer medical studies that do not have a placebo group.
Small Molecule
TPST-1495 + Pembrolizumab for Cancer
This trial is testing a new drug, TPST-1495, to see if it is safe and effective in treating subjects with advanced solid tumors. The study will also look at the side effects of the drug and how it works in the body.
Behavioral Intervention
Patient Navigation for Head and Neck Cancer
This trial is testing a new patient navigation intervention to decrease delays and racial disparities in postoperative radiation therapy (PORT) after surgery for head and neck cancer squamous cell carcinoma (HNSCC).
View More Head And Neck Cancer Trials
See another 59 medical studies focused on head and neck cancer.
Frequently Asked Questions
Introduction to head and neck cancer
What are the top hospitals conducting head and neck cancer research?
When it comes to advancing research and treatment options for head and neck cancer, several top hospitals are leading the way. In Boston, Dana Farber Cancer Institute is at the forefront with six active clinical trials focused on this complex condition. While they may not have any completed trials in their history specifically dedicated to head and neck cancer, their expertise in oncology positions them as a trusted institution for patients seeking cutting-edge treatment options. Similarly committed to innovation is Washington University School of Medicine in Saint Louis, where researchers are currently conducting five active head and neck cancer trials. Their dedication to finding new solutions for patients underscores the importance of ongoing research in this field.
In Houston, the University of Texas MD Anderson Cancer Center stands out as a renowned institution driving advancements in head and neck cancer care. With five ongoing clinical trials devoted exclusively to this disease, MD Anderson's multidisciplinary approach ensures that patients receive comprehensive, personalized treatment plans tailored to their specific needs. Meanwhile, at the University of Alabama at Birmingham (UAB), experts are actively engaged in four head and neck cancer trials aimed at improving outcomes for those affected by this challenging condition.
Finally, the UC San Diego Moores Cancer Center located in La Jolla rounds up our list of top hospitals contributing significantly towards combating head and neck cancers.. They too hold an impressive record with four current clinical trials focusing on enhancing treatments for these types of cancers; though like other institutions mentioned earlier ,they do not possess prior experiments under head or throat specialties but boasts state-of-the-art facilities ensuring patient access world-class resources while offering exceptional medical attention.
The collective efforts of these institutions highlight a commitment to pushing boundaries through innovative research and providing hope for individuals navigating their journey with head and neck cancer. By exploring novel therapies through rigorous clinical testing conducted by these esteemed hospitals across different regions nationwide we can look forward towards substantial improvements that will transform lives impacted by such conditions
Which are the best cities for head and neck cancer clinical trials?
When it comes to head and neck cancer clinical trials, several cities show promise in their research efforts. Chicago, Illinois leads the pack with 20 active trials focusing on treatments like Durvalumab and Pembrolizumab. Boston, Massachusetts closely follows with 19 ongoing studies investigating interventions such as Palbociclib and cetuximab. Additionally, Portland, Oregon and Houston, Texas both demonstrate significant contributions to the field with 14 active trials each exploring various treatment options including pralsetinib (BLU-667) and OSI-774. Finally, Los Angeles, California rounds out the list with 12 ongoing studies centered around interventions like cetuximab and GC4419 (avasopasem manganese) 90 mg. These cities provide hope for individuals battling head and neck cancer by offering access to cutting-edge clinical trials that may lead to improved outcomes and enhanced quality of life.
Which are the top treatments for head and neck cancer being explored in clinical trials?
The field of head and neck cancer research is making significant strides, with several cutting-edge treatments being investigated in clinical trials. Leading the pack is pembrolizumab, an immunotherapy drug that has shown promise in multiple studies. Another notable contender is cetuximab, a targeted therapy that specifically inhibits certain proteins involved in cancer growth. Additionally, chemoradiotherapy combinations are being explored as potential treatment options for head and neck cancer patients. These innovative approaches hold great potential to improve outcomes and provide hope for those affected by this challenging disease.
What are the most recent clinical trials for head and neck cancer?
Exciting advancements in the field of head and neck cancer research offer hope to patients seeking new treatment options. One such breakthrough is zimberelimab, a promising drug currently undergoing Phase 1 clinical trials for head and neck cancer. Additionally, venlafaxine, already approved for other conditions, is now being studied in Phase 4 trials as a potential therapy for this type of cancer. Another trial focuses on the use of pembrolizumab alone in participants with head and neck cancer, aiming to evaluate its effectiveness in Phase 2 studies. Furthermore, dermaprazole has shown promise during Phase 2 trials as a potential treatment option for this challenging disease. Lastly, SQZ-eAPC-HPV is being investigated through combined Phase 1 and Phase 2 trials to explore its efficacy against head and neck cancer. As these clinical trials progress, they bring us closer to improved outcomes and better quality of life for those affected by head and neck cancer
What head and neck cancer clinical trials were recently completed?
Recently completed clinical trials aimed at advancing treatment options for head and neck cancer have shown promising results. One notable trial, sponsored by the National Cancer Institute (NCI), concluded in September 2021. The study examined the efficacy of a novel therapy called Cetuximab in improving outcomes for patients with advanced head and neck squamous cell carcinoma. This breakthrough research offers hope for individuals battling this challenging form of cancer and underscores the ongoing efforts to find innovative solutions within the field of oncology.